Design Therapeutics’ Friedreich’s ataxia data; Vincentage’s obesity results from Chinanews2026-05-18T14:56:46+00:00May 18th, 2026|Endpoints News|
Aardvark’s next move after clinical hold; Alumis’ verdict on Acelyrin assetnews2026-05-15T14:22:19+00:00May 15th, 2026|Endpoints News|
Degron, CREATE, TenNor raise capital; Cabaletta posts CAR-T datanews2026-05-14T14:42:33+00:00May 14th, 2026|Endpoints News|
Abeona pivots to T cells; AstraZeneca’s rare disease drug passes Phase 3news2026-05-13T15:36:52+00:00May 13th, 2026|Endpoints News|
Alkermes’ narcolepsy Phase 3 success; Boehringer’s antibody dealnews2026-05-12T13:37:31+00:00May 12th, 2026|Endpoints News|
New home for Novo’s Parkinson’s cell therapy; GSK’s deal to sell drug in Chinanews2026-05-11T15:11:26+00:00May 11th, 2026|Endpoints News|
FDA delays Leqembi decision; Artiva raises $300M; Pharvaris prices offeringnews2026-05-08T15:09:06+00:00May 8th, 2026|Endpoints News|
Entrada stock falls on Duchenne data; Wegovy expands accessnews2026-05-07T15:04:25+00:00May 7th, 2026|Endpoints News|
Madrigal’s Rezdiffra beats estimates; Gilead cuts jobs; Banyan debutsnews2026-05-06T15:17:19+00:00May 6th, 2026|Endpoints News|
Second life for gene therapy; Takeda Phase 2/3 win; UK cancer biotech’s $83Mnews2026-05-05T15:37:27+00:00May 5th, 2026|Endpoints News|
